TOCILIZUMAB, OBINUTUZUMAB, GLOFITAMAB, GLOFITAMAB clinical trials

A phase II, multicenter study of GlOfitamab in patients with mantle cell Lymphoma and inaDequate response or relapse following CAR T-cell therapy (GOLD)

This study looks at a new drug, glofitamab, for people with a type of blood cancer called Mantle Cell Lymphoma. It's for patients whose cancer has come back or hasn't responded well to a previous treatment called CAR T-cell therapy.